GlassScriptPhysician profile
Carmine J Defusco
NPI 1942270616
$3,333.20
in general payments reported to CMS, 2019-2025
23 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $261 · 2021: $452 · 2022: $719 · 2023: $928 · 2024: $264 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,117.46 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $841.51 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $245.21 | 2019-2025 | |
| Amgen INC. | $153.29 | 2022-2025 | Tezspire |
| Optinose US, INC. | $127.63 | 2019-2023 | |
| Pfizer INC. | $114.26 | 2022-2025 | |
| Kaleo, INC. | $113.82 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.74 | 2021-2022 | |
| Alk-Abello, INC | $79.02 | 2021-2023 | Odactra, Ragwitek, Grastek |
| Teva Pharmaceuticals USA, INC. | $73.49 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $59.34 | 2021-2025 | Orladeyo |
| Covis Pharma Gmbh | $52.15 | 2019-2020 | |
| Genentech USA, INC. | $48.53 | 2022-2024 | Xolair |
| Abbvie INC. | $44.58 | 2023 | Lo Loestrin Fe |
| Csl Behring | $40.61 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.07 | 2019-2025 | |
| Horizon Therapeutics Plc | $15.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.82 | 2020 | |
| Vifor Pharma, INC. | $14.81 | 2024 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $14.76 | 2023 | Takhzyro |
| Hikma Pharmaceuticals USA | $14.21 | 2022 | |
| Shire North American Group INC | $13.72 | 2019 | |
| Merck Sharp & Dohme LLC | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmine Defusco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.